IS2481B - Lyfjablanda sem inniheldur 5HT1 viðtakagerandefni - Google Patents

Lyfjablanda sem inniheldur 5HT1 viðtakagerandefni

Info

Publication number
IS2481B
IS2481B IS7293A IS7293A IS2481B IS 2481 B IS2481 B IS 2481B IS 7293 A IS7293 A IS 7293A IS 7293 A IS7293 A IS 7293A IS 2481 B IS2481 B IS 2481B
Authority
IS
Iceland
Prior art keywords
pharmaceutical composition
composition containing
receptor agonists
agonists
receptor
Prior art date
Application number
IS7293A
Other languages
English (en)
Other versions
IS7293A (is
Inventor
William Baker Robert
David Dow Alan
John Summers Simon
Westrup Julian
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7293A publication Critical patent/IS7293A/is
Publication of IS2481B publication Critical patent/IS2481B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7293A 2001-12-05 2004-06-03 Lyfjablanda sem inniheldur 5HT1 viðtakagerandefni IS2481B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129117.8A GB0129117D0 (en) 2001-12-05 2001-12-05 Pharmaceutical composition
PCT/EP2002/013715 WO2003047552A2 (en) 2001-12-05 2002-12-04 Pharmaceutical composition comprising a 5ht1 receptor agonist

Publications (2)

Publication Number Publication Date
IS7293A IS7293A (is) 2004-06-03
IS2481B true IS2481B (is) 2008-12-15

Family

ID=9927051

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7293A IS2481B (is) 2001-12-05 2004-06-03 Lyfjablanda sem inniheldur 5HT1 viðtakagerandefni

Country Status (29)

Country Link
US (1) US20050032867A1 (is)
EP (2) EP1450770B1 (is)
JP (1) JP3699969B2 (is)
KR (1) KR100591237B1 (is)
CN (1) CN1289069C (is)
AR (1) AR037627A1 (is)
AT (1) ATE291900T1 (is)
AU (1) AU2002358602B2 (is)
BR (1) BR0214497A (is)
CA (1) CA2469019C (is)
CO (1) CO5580741A2 (is)
DE (1) DE60203537T2 (is)
ES (1) ES2236608T3 (is)
FI (1) FI20022128A (is)
GB (1) GB0129117D0 (is)
HK (1) HK1069111A1 (is)
HU (1) HU229313B1 (is)
IL (1) IL161997A (is)
IS (1) IS2481B (is)
MX (1) MXPA04005420A (is)
MY (1) MY129314A (is)
NO (1) NO329896B1 (is)
NZ (1) NZ532829A (is)
PL (1) PL194702B1 (is)
PT (1) PT1450770E (is)
RU (1) RU2285526C2 (is)
TW (1) TWI240638B (is)
WO (1) WO2003047552A2 (is)
ZA (1) ZA200403849B (is)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
MXPA05010070A (es) 2003-04-11 2005-11-23 Pfizer Combinacion farmaceutica.
BRPI0410807A (pt) * 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20070259040A1 (en) * 2006-05-01 2007-11-08 Cherukuri S R Novel triptan formulations and methods for making them
US20080081072A1 (en) * 2006-09-30 2008-04-03 Cherukuri S R Resin-complex granulation for water-soluble drugs and associated methods
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
US11364225B2 (en) 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027827D0 (en) * 1990-12-21 1991-02-13 Glaxo Laboratoires Pharmaceutical compositions
US5468504A (en) * 1990-12-21 1995-11-21 Laboratoires Glaxo S.A. Effervescent pharmaceutical compositions
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
AU2640599A (en) * 1998-02-26 1999-09-15 Banyu Pharmaceutical Co., Ltd. An orally disintegrating composition and its manufacturing method
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR20010107754A (ko) * 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine

Also Published As

Publication number Publication date
DE60203537D1 (de) 2005-05-04
CA2469019C (en) 2005-09-13
AU2002358602B2 (en) 2005-05-26
BR0214497A (pt) 2004-10-19
NO20025805L (no) 2003-06-06
EP1450770B1 (en) 2005-03-30
AU2002358602A1 (en) 2003-06-17
HK1069111A1 (en) 2005-05-13
HU229313B1 (en) 2013-10-28
AR037627A1 (es) 2004-11-17
MY129314A (en) 2007-03-30
KR100591237B1 (ko) 2006-06-19
HUP0402178A2 (hu) 2005-02-28
NO329896B1 (no) 2011-01-24
MXPA04005420A (es) 2004-10-11
JP3699969B2 (ja) 2005-09-28
IS7293A (is) 2004-06-03
EP1527773A1 (en) 2005-05-04
CN1289069C (zh) 2006-12-13
CA2469019A1 (en) 2003-06-12
JP2005515991A (ja) 2005-06-02
TWI240638B (en) 2005-10-01
RU2004120292A (ru) 2005-04-10
HUP0402178A3 (en) 2011-05-30
ATE291900T1 (de) 2005-04-15
FI20022128A0 (fi) 2002-12-03
GB0129117D0 (en) 2002-01-23
US20050032867A1 (en) 2005-02-10
NZ532829A (en) 2005-05-27
CO5580741A2 (es) 2005-11-30
PL194702B1 (pl) 2007-06-29
ES2236608T3 (es) 2005-07-16
CN1610539A (zh) 2005-04-27
IL161997A (en) 2005-12-18
TW200304384A (en) 2003-10-01
WO2003047552A3 (en) 2003-09-25
KR20050044720A (ko) 2005-05-12
IL161997A0 (en) 2005-11-20
NO20025805D0 (no) 2002-12-03
ZA200403849B (en) 2005-10-26
WO2003047552A2 (en) 2003-06-12
EP1450770A2 (en) 2004-09-01
PL370669A1 (en) 2005-05-30
RU2285526C2 (ru) 2006-10-20
FI20022128A (fi) 2003-06-06
PT1450770E (pt) 2005-08-31
DE60203537T2 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
HK1069111A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist.
NO20032678L (no) NMDA reseptor agonist farmasöytiske sammensetninger
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
FI20011478A (fi) Farmaseuttinen koostumus
IS2893B (is) Lyfjasamsetning sem inniheldur lantanefnasambönd
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
IS8287A (is) Lyfjablanda sem felur í sér levóþýroxínnatríum
IS7051A (is) Lyfjasamsetningar
IS7458A (is) Stöðug lyfjablanda sem inniheldur þátt VIII
NO20034556D0 (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DK1465923T3 (da) Corticotroprinafgivende faktor 2-receptoragonister
IS7219A (is) Lyfjablanda sem inniheldur (R) -bíkalútamíð
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
IS7581A (is) Lyfjasamsetning
EE200300378A (et) Farmatseutiline kompositsioon
DK1450770T3 (da) Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
DK1347760T3 (da) Farmaceutiske kompositioner med NMDA receptor agonister
FI5468U1 (fi) Farmaseuttinen koostumus